Kura Oncology (KURA) is making a bold structural move to push its diabetes ambitions forward. On Wednesday, the company announced it's spinning out a new subsidiary called Caspian Therapeutics, backed by a fresh $50 million financing round. The lead investor is BVF Partners, and the roster includes the T1D Fund, Invus, Montanova, Eli Lilly and Co. (LLY), Kura itself, members of Kura's leadership team, and a few other investors.
The whole point is to give menin inhibition a dedicated home, with Caspian focused on expanding development capacity around that approach. Think of it as Kura saying, "This work is important enough to deserve its own shop."
Building Around KO-7246
Caspian is being built around KO-7246, which Kura describes as a next-generation, highly selective menin inhibitor designed specifically for chronic metabolic diseases. Along with the drug candidate, Kura is contributing related intellectual property and know-how to the new entity.
The financing is earmarked to move KO-7246 through IND-enabling development and into initial clinical proof-of-concept studies in diabetes. But that's not all. There's also a second menin inhibitor candidate in the pipeline, aimed at diabetes and cardiometabolic diseases, and this funding will help advance that program too.
How It's Structured
Caspian won't be a totally independent operation. It will have its own dedicated leadership and external capital, but it will tap into Kura's research, development, and corporate capabilities through an intercompany services arrangement. Kura will keep roughly half ownership of Caspian and will have board representation. So it's a bit like a startup with a safety net, or a parent company letting a promising child branch out while keeping a close eye.
What Analysts Think
Wall Street seems to like the direction. Kura carries a Buy rating with an average price target of $25.00. Recent analyst moves include Citizens maintaining a Market Outperform rating with a $24.00 price target on August 24, and Wedbush raising its price target to $38.00 with an Outperform rating on August 13.
Momentum Check
Looking at MarketDash's scorecard, Kura is showing some serious momentum. The stock scores a 92.68 on momentum, which is considered bullish and indicates strong relative strength versus the broader market. Other factor scores aren't available here, but the story is pretty clear: this is a momentum-driven stock right now. Trend-followers might want to keep an eye on it as long as it holds its key moving averages and doesn't lose steam.
As for the price action, Kura shares were down 1.04% at $12.39 at the time of publication on Wednesday.
